HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hing, E. Articles by Brett, K. M. Search for Related Content PubMed PubMed Citation Articles by Hing, E. Articles by Brett, K. M. Related Collections Menopause and HRT Reproductive endocrinology

Changes in U.S. Prescribing Patterns of Menopausal Hormone Therapy, 2001–2003

From the ¹Division of Health Care Statistics, and ²Office of Analysis and Epidemiology, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland.

OBJECTIVE: In 2002, the combination estrogen–progestin hormone therapy (HT) treatment arm of the Women’s Health Initiative was terminated early because cardiovascular and cancer risks were identified, while the estrogen-only therapy (ET) arm of this trial continued. We investigated hormone therapy prescription practice changes between 2001 and 2003 to explore the effects of the clinical trial results.

METHODS: Data were obtained from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey for the years 2001 through 2003. These nationally representative surveys sample medical encounters in nonfederally employed physician’s offices and outpatient departments of nonfederal short-stay and general hospitals. The proportion and rate of visits with ET and HT prescriptions were calculated. Logistic regression was used to estimate change over time accounting for patient and provider characteristics.

RESULTS: Between 2001 and 2003, the number of visits with menopausal hormone prescriptions fell from 26.5 million to 16.9 million. Almost three-quarters of hormone visits were for ET prescriptions. The decrease in the rate of visits was slightly larger for HT prescription visits (44%) than ET prescription visits (35%). The rate of decline was highest among women 50 years of age and over. After controlling for covariates, there was no significant difference in the decline by hormone type.

CONCLUSION: These nationally representative data indicate substantial declines in menopausal hormone prescriptions coinciding with clinical trial results on HT. These declines occurred among all types of therapy and patient characteristics.

LEVEL OF EVIDENCE: II-3

This article has been cited by other articles:

				C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463. [Abstract] [Full Text] [PDF]

				J. H. Liu Evolving Approaches in the Treatment of Menopausal Symptoms. Obstet. Gynecol., July 1, 2006; 108(1): 4 - 5. [Full Text] [PDF]